SOE-MOE KYAW: Open Payments
NPI 1871534461 · UPLAND, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$824 in 21 payments from 10 companies in 2025. Trend: 2023 $608 · 2024 $469 · 2025 $824
Food & beverage: $824
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 2 | $252 |
| E.R. Squibb & Sons, L.L.C. | 3 | $179 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $122 |
| Axsome Therapeutics, Inc. | 5 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Neurocrine BioSciences, Inc. | 1 | $33 |
| Alkermes, Inc. | 1 | $29 |
| Corium, LLC | 1 | $21 |
| ABBVIE INC. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
Products named: INVEGA SUSTENNA, COBENFY, CAPLYTA, Auvelity, TRINTELLIX, INGREZZA, VIVITROL, Azstarys.
Industry payments across CA — which companies pay providers there.
